Latest Governance And Leadership News

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

SenSen Networks reported a 16.7% rise in annualised recurring revenue to $11.7 million and a 23.6% EBITDA increase to $2.0 million in FY26, while expanding its SenDISA platform into environmental enforcement with EPA Victoria.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Hubify Limited posted an 89% jump in FY26 EBITDA to $0.66 million despite a 5% revenue dip, driven by a strategic shift to higher-margin managed technology and advisory services and a robust cash position of $3.79 million.

Redox Limited posted a strong FY26 with record revenue of $1.33 billion, a 19.2% jump in statutory net profit, and a 4% dividend increase, while announcing a board leadership transition.

Urbanise.com Limited reported 14.3% revenue growth to $15 million in FY2026, significantly narrowing its net loss to $0.9 million while advancing a NAB partnership pilot and launching AI features.

L1 Global Long Short Fund (ASX:GLS) reported a striking $121.3 million net profit for FY26 following its strategic reset, declaring a fully franked 2.00 cent final dividend and targeting 8.00 cents per share for FY27.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

Atturra Limited’s FY26 results reveal a sharp net loss driven by a $22.8 million goodwill impairment, overshadowing a 17% revenue increase to $351.8 million. The company is banking on AI and strategic acquisitions to fuel a turnaround in FY27.

Jcurve Solutions (ASX:JCS) posted a significant financial turnaround in FY2026, with revenue climbing 16.3% to $13.28 million and normalised EBITDA more than doubling to $1.88 million, underpinned by disciplined cost control and recurring revenue growth.

3P Learning reports a statutory net profit of $9.9 million and a 26% rise in underlying EBITDA to $19.5 million for FY26, declaring a 3.52 cent dividend after more than a decade.